Research programme: monoclonal antibody therapeutics - Alethia BioTherapeutics

Drug Profile

Research programme: monoclonal antibody therapeutics - Alethia BioTherapeutics

Alternative Names: AB-0440; AB-0447; AB-25E9; AB-3A4; AB-3A4-ADC; AB-3D3; AB-IsoG; Anti-KAAG1 monoclonal antibody - Alethia BioTherapeutics; Anti-Siglec-15 monoclonal antibody - Alethia BioTherapeutics

Latest Information Update: 25 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alethia BioTherapeutics
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Membrane protein inhibitors; Siglec-15 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone resorption; Breast cancer; Ovarian cancer
  • Research Malignant melanoma; Renal cancer

Most Recent Events

  • 25 Nov 2015 Preclinical trials in Breast cancer in Canada (Parenteral)
  • 04 Jun 2013 Early research in Malignant melanoma in Canada (Parenteral)
  • 04 Jun 2013 Early research in Renal cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top